Get started

VERU

Where is VERU going?I am not a professional and don't work in finance. This is a technical analysis of the daily candles. I think in at least the short term you are going to see VERU make a drop. This opinion is only based on the fact that the MACD just crossed over. I originally thought with the green engulfing candle that we may continue the uptrend, but the lack of volume and the cross over on the MACD solidifies for me that we will be going down. Let me know what you think. I would love your feedback.
NASDAQ:VERUShort
by Adventure_Joe
VERU priming for an uptrend after dropping 20% in a week$VERU, an oncology bio-pharma company reported great earnings and then proceeded to drop 20% in the undertow of last week's bond market turmoil. It's earnings run-up anticipated great results as well. Looking to hold its .382 Fibonacci support level for next week in order to enter in. Happy Trading, from CJ -- aka the greatest FURU. To find out more about The Ultimate Stock Indicator on Tradingview, please check my public profile. 🚀🚀🚀🚀
NASDAQ:VERULong
by CJCHUN
2
Stock to watch: Veru Inc (NASDAQ: VERU)NASDAQ:VERU An interesting stock to watch. The asset is in a 1,5 month uptrend without major pullbacks + MACD Crossover indicator's Long signal is still in progress. The buy zone is marked out, targets are 12.5, 15, 18, 23,88 and towards the all-time high. Invalidation: closing below the gap. Disclaimer: This article should not be considered as financial or investment advice. Trading digital assets involve risk and may resolve in the loss of your capital. Always be sure to understand the amount of risk involved and do your research before taking any trading/investment steps.
NASDAQ:VERULong
by randomname11
$VERU - Bullish Trend Good YTD So FarVeru, Inc. is an oncology and urology biopharmaceutical company. It develops medicines for prostate cancer treatment and prostate cancer supportive care as well as urology specialty pharmaceuticals. Its oncology drug candidates includes VERU-111, an oral alpha and beta tubulin inhibitor, which is in a phase 1b/2 study for the treatment of metastatic castration resistant prostate cancer; Zuclomiphene citrate, which is in a phase 2 clinical trial for the treatment of hot flashes in men undergoing prostate cancer hormonal therapies; and VERU-100, a long-acting GnRH antagonist 3 month subcutaneous depot, planned phase 2 clinical trial for the treatment of hormone sensitive advanced prostate cancer. The company's urology specialty pharmaceutical drug candidate is TADFIN, a tadalafil and finasteride combination oral capsule, for the treatment of men with benign prostatic hyperplasia. Its commercial products include the FC2 Female/Internal condom for prevention of pregnancy and sexually transmitted infections and PREBOOST 4% benzocaine wipes for the prevention of premature ejaculation marketed as Roman Swipes by getroman.com. The company was founded by William R. Gargiulo Jr. and O.B. Parrish in 1996 and is headquartered in Miami, FL. SHORT INTEREST 52.79K 09/30/19 P/E Current -4.75 P/E Ratio (with extraordinary items) -7.87 Average Recommendation: BUY Average Target Price: 7.38
NASDAQ:VERULong
by DEXWireNews